A study of novel macrophage-targeting p38 MAPK inhibitor for the treatment of cancer.
Phase of Trial: Phase I
Latest Information Update: 20 Jan 2017
At a glance
- Drugs Mitogen-activated protein kinase inhibitors (Primary)
- Indications Cancer
- Focus Adverse reactions
- 20 Jan 2017 According to a Macrophage Pharma media release, the company expects to initiate this study in 2018.
- 20 Jan 2017 New trial record